Kadrovska organizacija/struktura i funkcionisanje centara za transplantaciju matičnih ćelija –  kako optimizovati program transplantacije?

Milena Todorović Balint; Bela Balint; Irena Đunić; Mihailo Smiljanić; Biljana Mihaljević

doi:10.5937/medrec2003109T

Milena Todorović Balint Klinika za hematologiju Kliničkog centra Srbije, Beograd
Bela Balint Institut za kardiovaskularne bolesti „Dedinje”, BeogradSrpska akademija nauka i umetnosti, Beograd, Srbija
Irena Đunić Klinika za hematologiju Kliničkog centra Srbije, Beograd, Medicinski fakultet Univerziteta u Beogradu, Srbija
Mihailo Smiljanić Klinika za hematologiju Kliničkog centra Srbije, Beograd
Biljana Mihaljević Klinika za hematologiju Kliničkog centra Srbije, Beograd, Medicinski fakultet Univerziteta u Beogradu

DOI: https://doi.org/10.5937/medrec2003109T

Ključne reči: limfadenopatija, diferencijalna dijagnoza

Sažetak

Kod većine pacijenata sa perifernom limfadenopatijom je lako identifikovati njen uzrok, koji je obično benigne prirode ili lokalizovan. Prevalencija maligniteta kod pacijenata sa limfadenopatijom u primarnoj zdravstvenoj zaštiti je procenjena na oko 1,1%. Identifikacija limfadenopatije uzrokovane malignitetom ili drugim teškim stanjima predstavlja kritičan izazov za lekare u primarnoj zdravstvenoj zaštiti. Glavni faktori rizika za malignitet su starost, čvrsti i fiksirani nodusi, supraklavikularna lokalizacija i trajanje limfadenopatije više od 2 nedelje. Posedovanje znanja o ovim ključnim faktorima rizika je kritično u tretiranju neobjašnjive limfadenopatije. Uz to, uzimanje kompletne anamneze, procena povezanih simptoma i detaljan fizički pregled mogu da pomognu u utvrđivanju da li je limfadenopatija benigna ili maligna. Neobjašnjiva limfadenopatija bez znakova ili simptoma teškog oboljenja ili maligniteta može biti praćena do mesec dana, nakon čega se indikuje specifično testiranje ili biopsija. Iako su moderne hematopatološke tehnike unapredile dijagnostičku preciznost aspiracije (biopsije) tankom iglom, eksciziona biopsija i dalje ostaje dijagnostička procedura prvog izbora.

Reference

Pravilnik o bližim uslovima za obavljanje zdravstvene delatnosti u zdravstvenim ustanovama i drugim oblicima zdravstvene službe („Službeni glasnik RS”, broj 107/05).

ISO9001:2015 Quality management systems – Requirements

ISO 13485:2016 Medical devices – QMS. https://www.iso.org/standard/59752.html

ISO. Medical laboratories -Particular requirements for quality and competence. ISO 15189:2007.

ISO/IEC 17025:2017. Best ISO 17025 quality manual. www.globalmanagergroup.com

ISO: General requirements for the competence of testing and calibration laboratories. ISO/IEC 17025:2005.

Nassar A, Srivastava A, Hashmi SK, Aljurf M. Establishing an HSCT Program with Limited Resources. In: Gluckman E, Niederwieser D, Aljur M, eds. Establishing a Hematopoietic Stem Cell Transplantation Unit. Springer; 2018. ISBN 978-3-319-59358-6 (eBook).

Thorsteinsdóttir H, Quach U, Martin DK, Daar AS, Singer PA. Introduction: promoting global health through biotechnology. Nat Biotechnol 2004; 22: 3-7.

Lee SJ. Outcomes research in hematopoietic cell transplantation. In: Appelbaum FR, Forman SJ, Negrin RS, Blime KG, eds. Thomas’ Hematopoietic Cell Transplantation. 4th ed. Chichester, UK: Wiley-Blackwell; 2004. p. 428-41.

Yu YB, Gau JP, You JY, Chern HH, Chau WK, Tzeng CH, Ho CH, Hsu HC. Cost-effectiveness of postremission intensive therapy in patients with acute leukemia. Ann Oncol 2006; 18(3): 529-34.

Imataki O, Kamioka T, Fukuda T, Tanosaki R, Takaue Y. Cost and effectiveness of reduced-intensity and conventional allogeneic hematopoietic stem cell transplantation for acute myelogenous leukemia and myelodysplastic syndrome. Support Care Cancer 2010; 18(12): 1565-9.

Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the Economic Evaluation of Health Care Programmes. 3. New York: Oxford University Press; 2005. p. 8-25. p. 38-48. p. 126-133.

World Health Organization. Basic Documents-48th Ed [Internet]. Geneva: WHO Press; 2014. http://apps.who.int/gb/bd

Stranges E, Russo CA, Friedman B. Procedures with the most rapidly increasing hospital costs, 2004–2007, HCUP Statistical Brief 82. Rockville: Agency for Healthcare Research and Quality. Dec 2009. http://www.hcup-us.ahrq.gov/reports/statbriefs/sb82.pdf

Griffiths RI, Bass EB, Powe NR, Anderson GF, Goodman S, Wingard JR. Factors influencing third party payer costs for allogeneic BMT. Bone Marrow Transplant 1993; 12(1): 43-8.

Preussler JM, Denzen EM, Majhail NS. Costs and cost-effectiveness of hematopoietic cell transplantation. Biol Blood Marrow Transplant 2012; 18(11): 1620-8.

Majhail NS, Mothukuri JM, Macmillan ML, Verneris MR, Orchard PJ, Wagner JE, Weisdorf DJ. Costs of pediatric allogeneic hematopoietic-cell transplantation. Pediatr Blood Cancer 2010; 54(1): 138-43.

Majhail NS, Mothukuri JM, Brunstein CG, Weisdorf DJ. Costs of hematopoietic cell transplantation: comparison of umbilical cord blood and matched related donor transplantation and the impact of posttransplant complications. Biol Blood Marrow Transplant 2009; 15(5): 564-73.

Saito AM, Zahrieh D, Cutler C, Ho VT, Antin JH, Soiffer RJ, Alyea EP, Lee SJ. Lower costs associated with hematopoietic cell transplantation using reduced-intensity vs high-dose regimens for hematological malignancy. Bone Marrow Transplant 2007; 40(3): 209-17.

Rizzo JD, Vogelsang GB, Krumm S, Frink B, Mock V, Bass EB. Outpatient-based bone marrow transplantation for hematologic malignancies: cost saving or cost shifting? J Clin Oncol 1999; 17(9): 2811-8.